Target Price | GBP136.22 |
Price | GBP105.50 |
Potential | 29.12% |
Number of Estimates | 22 |
22 Analysts have issued a price target AstraZeneca 2026 . The average AstraZeneca target price is GBP136.22. This is 29.12% higher than the current stock price. The highest price target is GBP171.71 62.75% , the lowest is GBP108.88 3.20% . | |
A rating was issued by 30 analysts: 27 Analysts recommend AstraZeneca to buy, 3 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the AstraZeneca stock has an average upside potential 2026 of 29.12% . Most analysts recommend the AstraZeneca stock at Purchase. |
23 Analysts have issued a sales forecast AstraZeneca 2025 . The average AstraZeneca sales estimate is GBP42.3b . This is 3.40% higher than the revenue of the last 12 months(TTM). The highest sales forecast is GBP43.7b 6.61% , the lowest is GBP39.8b 2.90% .
This results in the following potential growth metrics:
2024 | GBP40.3b | 18.03% |
---|---|---|
2025 | GBP42.3b | 5.13% |
2026 | GBP45.3b | 7.07% |
2027 | GBP47.7b | 5.18% |
2028 | GBP51.1b | 7.23% |
2029 | GBP54.0b | 5.52% |
18 Analysts have issued an AstraZeneca EBITDA forecast 2025. The average AstraZeneca EBITDA estimate is GBP15.0b . This is 17.83% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is GBP17.8b 39.66% , the lowest is GBP12.9b 1.43% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | GBP12.3b | 29.46% |
---|---|---|
2025 | GBP15.0b | 21.81% |
2026 | GBP16.7b | 11.36% |
2027 | GBP18.2b | 8.58% |
2028 | GBP20.0b | 10.07% |
2029 | GBP23.6b | 18.02% |
2024 | 30.60% | 9.68% |
---|---|---|
2025 | 35.46% | 15.87% |
2026 | 36.88% | 4.00% |
2027 | 38.07% | 3.23% |
2028 | 39.08% | 2.65% |
2029 | 43.71% | 11.85% |
15 AstraZeneca Analysts have issued a net profit forecast 2025. The average AstraZeneca net profit estimate is GBP7.6b . This is 31.60% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is GBP10.3b 77.31% , the lowest is GBP6.2b 7.80% .
This results in the following potential growth metrics and future Net Margins:
2024 | GBP5.2b | 18.14% |
---|---|---|
2025 | GBP7.6b | 45.39% |
2026 | GBP9.2b | 20.15% |
2027 | GBP10.3b | 12.72% |
2028 | GBP11.1b | 7.36% |
2029 | GBP13.6b | 22.36% |
2024 | 13.01% | 0.09% |
---|---|---|
2025 | 17.99% | 38.28% |
2026 | 20.19% | 12.23% |
2027 | 21.64% | 7.18% |
2028 | 21.66% | 0.09% |
2029 | 25.12% | 15.97% |
15 Analysts have issued a AstraZeneca forecast for earnings per share. The average AstraZeneca EPS is GBP4.91 . This is 32.35% higher than earnings per share in the financial year 2024. The highest EPS forecast is GBP6.62 78.44% , the lowest is GBP4.02 8.36% .
This results in the following potential growth metrics and future valuations:
2024 | GBP3.35 | 17.96% |
---|---|---|
2025 | GBP4.91 | 46.57% |
2026 | GBP5.90 | 20.16% |
2027 | GBP6.66 | 12.88% |
2028 | GBP7.15 | 7.36% |
2029 | GBP8.74 | 22.24% |
Current | 28.43 | 29.70% |
---|---|---|
2025 | 21.47 | 24.48% |
2026 | 17.87 | 16.77% |
2027 | 15.85 | 11.30% |
2028 | 14.76 | 6.88% |
2029 | 12.06 | 18.29% |
Based on analysts' sales estimates for 2025, the AstraZeneca stock is valued at an EV/Sales of 4.37 and an P/S ratio of 3.91 .
This results in the following potential growth metrics and future valuations:
Current | 4.52 | 25.54% |
---|---|---|
2025 | 4.37 | 3.38% |
2026 | 4.08 | 6.61% |
2027 | 3.88 | 4.92% |
2028 | 3.62 | 6.74% |
2029 | 3.43 | 5.23% |
Current | 4.04 | 26.80% |
---|---|---|
2025 | 3.91 | 3.28% |
2026 | 3.65 | 6.61% |
2027 | 3.47 | 4.92% |
2028 | 3.23 | 6.74% |
2029 | 3.06 | 5.23% |
Analyst | Rating | Action | Date |
---|---|---|---|
Berenberg Bank |
➜
Buy
|
Unchanged | May 16 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Apr 29 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Mar 26 2025 |
Shore Capital |
➜
Buy
|
Unchanged | Mar 07 2025 |
JP Morgan Cazenove |
➜
Overweight
|
Unchanged | Feb 19 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jan 27 2025 |
Berenberg Bank |
➜
Buy
|
Unchanged | Jan 06 2025 |
Analyst Rating | Date |
---|---|
Unchanged
Berenberg Bank:
➜
Buy
|
May 16 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Apr 29 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Mar 26 2025 |
Unchanged
Shore Capital:
➜
Buy
|
Mar 07 2025 |
Unchanged
JP Morgan Cazenove:
➜
Overweight
|
Feb 19 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 27 2025 |
Unchanged
Berenberg Bank:
➜
Buy
|
Jan 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.